skip to main content

News Archive

Date: 06/14/2013
Researchers at the University of Michigan Rogel Cancer Center looked at 169 cancer clinical practice guidelines for lung, breast, prostate and colorectal cancers and found that none of the guidelines fully met standards set in 2011 by the Institute of Medicine.
Date: 06/13/2013
Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, University of Michigan Rogel Cancer Center researchers are reporting.
Date: 06/10/2013
Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, University of Michigan Rogel Cancer Center researchers are reporting.
Date: 06/10/2013
Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, University of Michigan Rogel Cancer Center researchers are reporting." />
Date: 06/01/2013
Leaders from the University of Michigan Rogel Cancer Center and other Big Ten universities' cancer centers will kick-off the Big Ten Cancer Research Consortium on June 1 in Chicago.
Date: 05/29/2013
Aging parents may offer health benefits to children, says University of Exeter study involving U-M researcher.
Date: 05/24/2013
A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to better treatments for prostate cancer.
Date: 05/21/2013
Peripherally inserted central catheters have become many clinicians' go-to for IV delivery of antibiotics, nutrition, chemotherapy, and other medications, But compared to other central venous catheters (CVCs), these commonly-used catheters (known as PICCs) more than double the risk of dangerous blood clots - especially among patients who are critically ill or who have cancer, according to a new University of Michigan Health System study.
Date: 05/17/2013
With a focus on shared decision making between doctors and patients, more studies needed to determine how decision aids help guide choices for cancer screening.
Date: 05/11/2013
Written by: Beata Mostafavi. Media Inquiries: 734-764-2220, 8 a.m.-5 p.m. ET or [email protected]

Pages